[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100594378":3},{"organization":4,"armGroups":7,"interventions":15,"overallOfficials":21,"centralContacts":27,"locations":33,"responsibleParty":165,"collaborators":21,"id":169,"slug":170,"hasResults":171,"nctId":172,"briefTitle":173,"officialTitle":174,"acronym":175,"eligibilityCriteria":176,"healthyVolunteers":171,"sex":177,"minAge":178,"maxAge":21,"enrollmentInfo":179,"targetDuration":21,"studyType":182,"phases":183,"briefSummary":186,"conditions":187,"keywords":192,"overallStatus":128,"whyStopped":21,"lastUpdateSubmitDate":199,"lastUpdatePostDateStruct":200,"startDateStruct":203,"completionDateStruct":205,"leadSponsor":207,"locationsCount":208},{"fullName":5,"class":6},"Leiden University Medical Center","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"[18F]-FAPI-74 PET\u002FCT","EXPERIMENTAL","3.0 MBq \\[18F\\]-FAPI-74 will be administered intravenously 60 minutes before PET\u002FCT scanning. Scanning time will be dependent on the type of scanner in the participating center, but will take approximately 20 minutes.",[13,14],"Diagnostic Test: [18F]FAPI-74 PET\u002FCT","Drug: [18F]-FAPI-74",[16,22],{"type":17,"name":18,"description":19,"armGroupLabels":20,"otherNames":21},"DIAGNOSTIC_TEST","[18F]FAPI-74 PET\u002FCT","Patients included in the study will undergo FAPI-PET\u002FCT after initial staging with gastroscopy and a contrast-enhanced CT of thorax and abdomen, but before undergoing a staging laparoscopy. Based on the results of the FAPI-PET\u002FCT, the MDT and\u002For treating physician will decide on the next step: confirming possible malignant lesions on PET\u002FCT by biopsies (either percutaneous of by staging laparoscopy), or in case of negative PET\u002FCT, diagnostic laparoscopy.",[9],null,{"type":23,"name":24,"description":25,"armGroupLabels":26,"otherNames":21},"DRUG","[18F]-FAPI-74","\\[18F\\]-FAPI-74 will be administered intravenously 60 minutes before PET\u002FCT-scanning to be able to detect (metastases of) gastric cancer",[9],[28],{"name":29,"role":30,"phone":31,"phoneExt":21,"email":32},"Sarah Spruijt, M.D.","CONTACT","+31 71 526 6029","s.w.j.m.spruijt@lumc.nl",[34,51,64,74,87,100,113,126,139,152],{"facility":35,"status":36,"city":37,"state":21,"zip":21,"country":38,"countryCode":39,"cosmosGeoPoint":40,"geoPoint":45,"contacts":46},"ZGT","NOT_YET_RECRUITING","Almelo","Netherlands","NL",{"type":41,"coordinates":42},"Point",[43,44],6.6625,52.35667,{"lat":44,"lon":43},[47,49],{"name":48,"role":30,"phone":31,"phoneExt":21,"email":32},"Marc van Det, M.D., PhD",{"name":50,"role":30,"phone":21,"phoneExt":21,"email":21},"Leo Weijs, M.D., PhD",{"facility":52,"status":36,"city":53,"state":21,"zip":21,"country":38,"countryCode":39,"cosmosGeoPoint":54,"geoPoint":58,"contacts":59},"Amsterdam UMC","Amsterdam",{"type":41,"coordinates":55},[56,57],4.88969,52.37403,{"lat":57,"lon":56},[60,62],{"name":61,"role":30,"phone":31,"phoneExt":21,"email":32},"Mark van Berge Henegouwen, Professor, M.D.",{"name":63,"role":30,"phone":21,"phoneExt":21,"email":21},"Ben Zwezerijnen, M.D.",{"facility":65,"status":36,"city":53,"state":21,"zip":21,"country":38,"countryCode":39,"cosmosGeoPoint":66,"geoPoint":68,"contacts":69},"Netherlands Cancer Institute - Antoni van Leeuwenhoek",{"type":41,"coordinates":67},[56,57],{"lat":57,"lon":56},[70,72],{"name":71,"role":30,"phone":31,"phoneExt":21,"email":32},"Johanna van Sandick, M.D., PhD",{"name":73,"role":30,"phone":21,"phoneExt":21,"email":21},"Emilia Owers, M.D., PhD",{"facility":75,"status":36,"city":76,"state":21,"zip":21,"country":38,"countryCode":39,"cosmosGeoPoint":77,"geoPoint":81,"contacts":82},"Rijnstate","Arnhem",{"type":41,"coordinates":78},[79,80],5.91111,51.98,{"lat":80,"lon":79},[83,85],{"name":84,"role":30,"phone":31,"phoneExt":21,"email":32},"Wim Oyen, Professor, M.D.",{"name":86,"role":30,"phone":21,"phoneExt":21,"email":21},"Bart Witteman, M.D., PhD",{"facility":88,"status":36,"city":89,"state":21,"zip":21,"country":38,"countryCode":39,"cosmosGeoPoint":90,"geoPoint":94,"contacts":95},"Catharina Ziekenhuis","Eindhoven",{"type":41,"coordinates":91},[92,93],5.47778,51.44083,{"lat":93,"lon":92},[96,98],{"name":97,"role":30,"phone":31,"phoneExt":21,"email":32},"Misha Luyer, M.D., PhD",{"name":99,"role":30,"phone":21,"phoneExt":21,"email":21},"Nanda Louwers, M.D., PhD",{"facility":101,"status":36,"city":102,"state":21,"zip":21,"country":38,"countryCode":39,"cosmosGeoPoint":103,"geoPoint":107,"contacts":108},"Zuyderland","Geleen",{"type":41,"coordinates":104},[105,106],5.82917,50.97417,{"lat":106,"lon":105},[109,111],{"name":110,"role":30,"phone":31,"phoneExt":21,"email":32},"Jan Stoot, M.D., PhD",{"name":112,"role":30,"phone":21,"phoneExt":21,"email":21},"Wendy Schreurs, M.D.",{"facility":114,"status":36,"city":115,"state":21,"zip":21,"country":38,"countryCode":39,"cosmosGeoPoint":116,"geoPoint":120,"contacts":121},"UMC Groningen","Groningen",{"type":41,"coordinates":117},[118,119],6.56667,53.21917,{"lat":119,"lon":118},[122,124],{"name":123,"role":30,"phone":31,"phoneExt":21,"email":32},"Walter Noordzij, M.D., PhD",{"name":125,"role":30,"phone":21,"phoneExt":21,"email":21},"Boudewijn van Etten, M.D., PhD",{"facility":127,"status":128,"city":129,"state":21,"zip":21,"country":38,"countryCode":39,"cosmosGeoPoint":130,"geoPoint":134,"contacts":135},"Leids Universitair Medisch Centrum","RECRUITING","Leiden",{"type":41,"coordinates":131},[132,133],4.49306,52.15833,{"lat":133,"lon":132},[136,137],{"name":29,"role":30,"phone":31,"phoneExt":21,"email":32},{"name":138,"role":30,"phone":21,"phoneExt":21,"email":21},"Lioe-Fee de Geus-Oei, Professor, M.D.",{"facility":140,"status":36,"city":141,"state":21,"zip":21,"country":38,"countryCode":39,"cosmosGeoPoint":142,"geoPoint":146,"contacts":147},"Erasmus MC","Rotterdam",{"type":41,"coordinates":143},[144,145],4.47917,51.9225,{"lat":145,"lon":144},[148,150],{"name":149,"role":30,"phone":31,"phoneExt":21,"email":32},"Erik Vegt, M.D., PhD",{"name":151,"role":30,"phone":21,"phoneExt":21,"email":21},"Bas Wijnhoven, Professor, M.D.",{"facility":153,"status":36,"city":154,"state":21,"zip":21,"country":38,"countryCode":39,"cosmosGeoPoint":155,"geoPoint":159,"contacts":160},"UMC Utrecht","Utrecht",{"type":41,"coordinates":156},[157,158],5.12222,52.09083,{"lat":158,"lon":157},[161,163],{"name":162,"role":30,"phone":31,"phoneExt":21,"email":32},"Jelle Ruurda, Professor, M.D.",{"name":164,"role":30,"phone":21,"phoneExt":21,"email":21},"Marnix Lam, Professor, M.D.",{"type":166,"investigatorFullName":167,"investigatorTitle":168,"investigatorAffiliation":5,"oldNameTitle":21,"oldOrganization":21},"PRINCIPAL_INVESTIGATOR","Lioe-Fee de Geus-Oei, MD PhD","Prof. dr.","100594378","phase-2-18ff-fapi-petct-and-laparoscopy-in-staging-advanced-gastric-cancer-100594378",false,"NCT07018661","[18F]F-FAPI PET\u002FCT and Laparoscopy in Staging Advanced Gastric Cancer","[18F]F-FAPI PET\u002FCT and LAparoscopy in STagIng Advanced Gastric Cancer - a Multicenter Prospective Study","PLASTIC-3","Inclusion Criteria:\n\n* Histologically proven adenocarcinoma of the stomach or the esophagogastric junction (Siewert type III), by gastroscopy;\n* Age greater than or equal to 18 years;\n* Surgically resectable, advanced tumor (cT3-4b, N0-3, M0), as determined on gastroscopy and a contrast-enhanced CT of thorax and abdomen. Intention to perform a gastrectomy, based on a multidisciplinary team meeting and shared decision making;\n* Patients must have given written informed consent;\n* Patients who have recently participated in an interventional study with an investigational medicinal product (IMP) may only participate if an interaction with study procedures is deemed unlikely by the study team (e.g. based on mechanism or washout period).\n\nExclusion Criteria:\n\n* Siewert type I-II esophagogastric junction tumor;\n* Unfit or unwilling to undergo study procedures;\n* Unfit or unwilling to undergo surgery;\n* Pregnancy at time of the \\[18F\\]AlF-FAPI-74 PET\u002FCT scan, due to the investigational PET radiation burden;\n* Incapacitated subjects without decision-making capacity;\n* Medical or psychiatric conditions that compromise the patient's ability to give informed consent;\n* Illiterate patients unable to complete the resource use and quality of life questionnaires;\n* Inability to undergo PET\u002FCT scans due to factors such as claustrophobia, weight limits, or the inability to lie flat for the duration of the scan (approximately 30 minutes).","ALL","18 Years",{"count":180,"type":181},250,"ESTIMATED","INTERVENTIONAL",[184,185],"PHASE2","PHASE3","The goal of this clinical trial is to learn if a new type of scan, FAPI-PET\u002FCT, can help find metastases of gastric cancer. We want to know how well this scan works for this purpose and whether it is less burdensome for patients compared to the methods we currently use to find metastases.\n\nThe main questions it aims to answer are:\n\n* In how many patients can FAPI-PET\u002FCT find metastases, which leads to a change in their treatment plan as decided by their medical team, such as avoiding unnecessary surgeries and changing from treatment meant to cure the disease to treatment focused on comfort (palliative treatment)?\n* In how many patients does FAPI-PET\u002FCT change the diagnostic process as decided by their medical team, like more biopsies or imaging, or changing the type (extent) of surgery needed?\n\nApart from the usual care gastric cancer patients receive, participants will:\n\n* Undergo one additional scan, which will take approximately 2 hours in total (excluding travel time)\n* Complete a number of questionnaires, which will take approximately 4 hours in total",[188,189,190,191],"Locally Advanced Gastric Adenocarcinoma","STOMACH NEOPLASM","Gastric Cancer","PET-CT",[193,194,195,196,197,190,198],"FAPI","18F-FAPI-74","PET\u002FCT","Imaging biomarker","Gastrectomy","Diagnostics","2025-08-20",{"date":201,"type":202},"2025-08-27","ACTUAL",{"date":204,"type":202},"2025-07-03",{"date":206,"type":181},"2029-01",{"name":5,"class":6},10]